FindTrial
Sign In

T- Dxd

DRUG2 trials

Sponsors

AstraZeneca, The First Affiliated Hospital with Nanjing Medical University

Conditions

Additional Indications Below for Module 4 and 5Biliary CancerBladder CancerBreast CancerCervical CancerColorectal CancerEndometrial CancerGastric Cancer

Phase 1

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Active, not recruitingNCT04644068
AstraZenecaAdditional Indications Below for Module 4 and 5, Biliary Cancer, Bladder Cancer +10
Start: 2020-11-12End: 2027-05-28Updated: 2026-02-19

Unknown Phase

Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study
CompletedNCT07108595
The First Affiliated Hospital with Nanjing Medical UniversityBreast Cancer
Start: 2021-01-01End: 2024-12-31Updated: 2025-08-07

Related Papers

Abstract 254: The PARP1-selective inhibitor and trapper saruparib achieves extended PARP1 target engagement <i>in vitro</i> , <i>in vivo</i> and in the clinic.
Cancer Research2026-04-03
Abstract PS1-10-28: Phase 1/2a trial of new generation PARP1-selective inhibitor saruparib + next generation selective ER degrader (SERD) camizestrant in patients (pts) with advanced/relapsed ER+/HER2-negative or low (HER2−) breast cancer (PETRA Module 6)
Clinical Cancer Research2026-02-17
Abstract 5618: Evaluating the combination of datopotamab deruxtecan (Dato-DXd) with AZD5305, a highly potent, PARP1-selective inhibitor, -in preclinical models
Cancer Research2024-03-223 citations
Modulatory Potential of Poly (ADP‐Ribose) Polymerase 1 (PARP1) in BRCA‐Mutated Tumors
European Journal of Cancer Care2024-01-011 citations
Abstract CT269: A highly sensitive and specific PARylation assay confirms significant and durable target engagement by AZD5305 in patients
Cancer Research2023-04-14
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Clinical Cancer Research2022-08-05154 citations
Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations
Cancer Research2022-06-1562 citations